DFTX (Definium Therapeutics) Other Current Liabilities: $56.88 Mil (As of Mar. 2026)


DFTX Definium Therapeutics Inc DFTX
32 GF Score
Price $47.04
! 5 Warning Signs
View Full Analysis

What is Definium Therapeutics Other Current Liabilities?

Definium Therapeutics DFTX +1.07% 32 Other Current Liabilities is $56.88 Mil as of Mar. 2026. GuruFocus rates DFTX with a GF Score™ of 32/100. The stock has 5 warning signs investors should review.

Definium Therapeutics's other current liabilities for the quarter that ended in Mar. 2026 was $56.88 Mil.

Definium Therapeutics's quarterly other current liabilities increased from Sep. 2025 ($45.61 Mil) to Dec. 2025 ($50.37 Mil) and increased from Dec. 2025 ($50.37 Mil) to Mar. 2026 ($56.88 Mil).

Definium Therapeutics's annual other current liabilities increased from Dec. 2023 ($21.00 Mil) to Dec. 2024 ($30.42 Mil) and increased from Dec. 2024 ($30.42 Mil) to Dec. 2025 ($50.37 Mil).

Definium Therapeutics Other Current Liabilities Related Terms

Definium Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Definium Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Definium Therapeutics Other Current Liabilities Chart

Definium Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial 2.30 13.10 21.00 30.42 50.37

Definium Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.08 24.13 45.61 50.37 56.88
DFTX
32GF Score
Definium Therapeutics Inc DFTX
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Definium Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $56.88 Mil mean?
Definium Therapeutics (DFTX) has a Other Current Liabilities of $56.88 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Definium Therapeutics.
Is Definium Therapeutics' Other Current Liabilities too high?
Definium Therapeutics' current Other Current Liabilities is $56.88 Mil. Overall, Definium Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Definium Therapeutics' Other Current Liabilities compare to LGND and XENE?
Definium Therapeutics' Other Current Liabilities of $56.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Definium Therapeutics. Definium Therapeutics's current Other Current Liabilities is $56.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Definium Therapeutics stock overvalued right now?
Definium Therapeutics (DFTX) has a current Other Current Liabilities of $56.88 Mil. The current Other Current Liabilities is $56.88 Mil. Definium Therapeutics' overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Definium Therapeutics (DFTX), the current Other Current Liabilities is $56.88 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Definium Therapeutics Business Description

Other Exchanges MMQ0:Germany
Address One World Trade Center, Suite 8500, New York, NY, USA, 10007
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
32GF Score

Get the complete analysis for DFTX

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$47.04
Price